BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/18/2021 11:27:35 AM | Browse: 604 | Download: 1310
 |
Received |
|
2021-01-28 14:59 |
|
Peer-Review Started |
|
2021-01-28 15:05 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-02-25 01:25 |
|
Revised |
|
2021-03-10 14:27 |
|
Second Decision |
|
2021-04-26 08:51 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2021-04-26 11:37 |
|
Articles in Press |
|
2021-04-26 11:37 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2021-05-14 19:47 |
|
Typeset the Manuscript |
|
2021-05-18 01:47 |
|
Publish the Manuscript Online |
|
2021-05-18 11:27 |
| ISSN |
2220-3249 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, General & Internal |
| Manuscript Type |
Minireviews |
| Article Title |
Angiotensin-converting enzyme 2 receptors, chronic liver diseases, common medications, and clinical outcomes in COVID-19 patients
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Wattana Leowattana |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Wattana Leowattana, BSc, MD, MSc, PhD, Associate Professor, Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, 420/6
rajavithi road, rachatawee, Bangkok 10400, Thailand. wattana.leo@mahidol.ac.th |
| Key Words |
SARS-CoV-2; COVID-19; Hepatobiliary tissue; Angiotensin converting enzyme 2; Chronic liver disease; Common medications; Clinical outcome |
| Core Tip |
With more than 100 million confirmed cases worldwide, hepatobiliary injury has been reported in many coronavirus disease 2019 (COVID-19) patients. The association between COVID-19 and hepatobiliary injury refers to any hepatobiliary damage during disease progression and treatment in COVID-19 patients with or without chronic liver diseases or common medications. Angiotensin-converting enzyme 2 receptor may be a significant factor in hepatobiliary derangement due to its highly expressed cholangiocyte, and it is also an entry point of severe acute respiratory syndrome coronaviruses 2. Moreover, drug-induced liver injury and cytokine storm may be an added risk in severe clinical outcomes. Close monitoring of the liver function in COVID-19 patients is mandatory. |
| Publish Date |
2021-05-18 11:27 |
| Citation |
Leowattana W. Angiotensin-converting enzyme 2 receptors, chronic liver diseases, common medications, and clinical outcomes in COVID-19 patients. World J Virol 2021; 10(3): 86-96 |
| URL |
https://www.wjgnet.com/2220-3249/full/v10/i3/86.htm |
| DOI |
https://dx.doi.org/10.5501/wjv.v10.i3.86 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
